drugset
drugset / Trial / NCT00243659

Study Evaluating B-Domain Deleted Recombinant Factor VIII (BDDrFVIII, ReFacto AF) in Patients With Hemophilia A Undergoing Elective Major Surgery

NCT00243659 ↗

Phase 3 Completed 30 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study will examine the efficacy and safety of ReFacto AF in patients with severe and moderately severe hemophilia A undergoing elective major surgery when administered by either bolus injections (BI) or continuous infusion (CI).

Timeline

Start
2006-04
Primary completion
2008-06
Completion
2008-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Moroctocog alfa Protein / enzyme biologic — Other

Indications

hemophilia A